MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » NxStage touts home hemodialysis study data

NxStage touts home hemodialysis study data

By

NxStage

NxStage Medical (NSDQ:NXTM) today released data from a study comparing home hemodialysis to traditional treatment in a skilled nursing facility, touting a lower risk of death and cardiovascular hospitalization for those treated more often with home hemodialysis.

Full results from the trial are slated to be presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting next week, the Lawrence, Mass.-based company said.

Investigators analyzed data collected from 3,619 patients treated in skilled nursing facilities between 2011 and 2015, and found that patients treated more frequently at home experienced a 34% lower risk of death and 23% lower risk of cardiovascular hospitalization compared to those receiving conventional hemodialysis in an SNF setting.

“Because patients undergoing dialysis have a high burden of cardiovascular disease, a 23% reduction in cardiovascular-related hospitalization is very clinically meaningful. These findings are even more impressive in the high-risk population of patients who reside in skilled nursing facilities,” Dr. Maria Rosa Costanzo of the Advocate Heart Institute said in a prepared statement.

“The significant survival and cardiovascular benefits associated with more frequent on-site home hemodialysis provides confidence and clear support for a new standard of care for dialysis patients within skilled nursing facilities. Home hemodialysis provided in the skilled nursing facility setting eliminates the needs and risks of high-cost and disruptive transportation to and from dialysis clinics, and by reducing hospitalization, more frequent on-site home hemodialysis can provide better patient health outcomes at a lower cost of care,” NxStage Medical chief medical officer said in a press release.

In late July, Fresenius (NYSE:FMS) said that it extended the deadline to close the $2 billion buyout of NxStage Medical by 90 days, pushing the deadline from August 7 to November 5.

In case you missed it

RSS From Medical Design & Outsourcing

  • Versapor® RC Membranes: The next generation of venting materials
    As the world leader in the design and production of membranes, filtration devices, and separation systems, Pall Corporation supplies products to nearly every industry in the world. Founded in 1946, Pall Corporation has set the standard for filtration solutions for 75 years and counting. Our customers have relied on us for their most sophisticated applications… […]
  • Tips to help bring your medical device from mind to market
    By Bret Ludwig, Ph.D. Senior Product Development Specialist, 3M Medical Materials & Technologies Great medical devices start with an idea—a spark. And from there, it might move to the back of a napkin or a notepad. But as development continues, the process can get trickier and more complex. In fact, turning an idea into a… […]
  • Salt baths increase stability in the medical device tempering process
    Calibration baths, like salt baths, were originally for calibrating temperature assets. But there’s another use for them: manufacturing Nitinol medical devices. Travis Porter, Fluke Calibration Nitinol is a nickel-titanium alloy that exhibits both thermal shape memory behavior and super-elasticity. It’s a great metal to use in medical devices because it’s possible to set the wire… […]
  • Traco Power announces new TMW 24 and TMW 36 series
    Traco Power (San Jose, Calif.) recently announced the company’s new TMW series of 24- and 36-W power supplies. The new power supplies are IP68 rated and fully encapsulated — with flexible options for PCB or chassis mounting for the medical and industrial markets. The TMW Series were also designed for flush box-mounting to support IoT… […]
  • Protolabs reports mixed-bag results for Q2
    Protolabs (NYSE: PRLB) posted second-quarter earnings today that missed the consensus forecast on Wall Street, though the company beat on revenue. The Maple Plain, Minn–based digital manufacturing outsourcer — which serves medtech and a host of other industries — reported profits of $12.9 million, or 47¢ per share, on sales of $123.0 million for the… […]
  • Integer beats The Street in Q2, boosts sales outlook
    Integer Holdings (NYSE:ITGR) posted second-quarter results today that beat the consensus forecast on Wall Street — boosting its 2021 sales outlook amid continued recovery from the COVID-19 pandemic. The Plano, Texas–based medical device contract manufacturing giant reported profits of $29.4 million, or 89¢ per share, on sales of $312.0 million for the three months ended… […]
  • Keep the end in mind when choosing a medtech partner
    There are five general categories of medtech vendor partners. If the end is apparent in the beginning, the correct type of partner will be clearer. Jim Reed, Minnetronix Medical Stephen Covey gave the business world this mantra in one of his bestsellers: “Start with the end in mind.” Whether they didn’t read the book or… […]
  • Orthofix launches Fiberfuse Strip bone graft
    Orthofix (NSDQ:OFIX) today announced that it has launched its FiberFuse Strip bone graft in the U.S. Lewisville, Texas–based Orthofix designed the FiberFuse Strip to be a preformed bone-graft strip for posterior cervical, posterior lumbar and degenerative spinal procedures. FiberFuse Strip is 100% bone and has a unique mixture of mineralized cancellous and demineralized cortical bone with… […]
  • Thermo Fisher Scientific beats The Street in Q2 results
    Thermo Fisher Scientific (NYSE:TMO) today posted second-quarter results that beat the overall consensus on Wall Street. The Waltham, Mass.–based company reported profits of $1.8 billion, or $4.61 per share, on sales of $9.3 billion for the three months ended July 1, 2021, for a bottom-line gain of 58.1% on sales growth of 34.1% compared with… […]
  • Choosing the Right Rubber Material and Process for Your Medical Parts
    When it’s time to design and develop a new medical device that calls for an elastomer component, there are a number of material options and manufacturing processes to consider. The long list of material properties impacting performance includes your prospective polymer’s end-use environment, chemical compatibility, hardness, compression set, tensile properties and manufacturability — to name… […]
  • 3M’s healthcare segment registers growth in Street-beating Q2
    3M (NYSE:MMM) reported second-quarter results that beat the consensus forecast — with the company’s healthcare segment showing especially robust growth. The St. Paul, Minn.–based company posted profits of $1.5 billion, or $2.59 per share, on sales of $9 billion for the three months ended June 30, 2021, for a 16.7% bottom-line gain on sales growth of… […]